NASDAQ:JNCE - Jounce Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $7.74 -0.09 (-1.15 %) (As of 07/18/2018 06:34 AM ET)Previous Close$7.83Today's Range$7.70 - $8.0952-Week Range$6.84 - $29.25Volume228,300 shsAverage Volume419,493 shsMarket Capitalization$254.35 millionP/E RatioN/ADividend YieldN/ABeta5.79 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Receive JNCE News and Ratings via Email Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:JNCE CUSIPN/A Webwww.jouncetx.com Phone857-259-3840 Debt Debt-to-Equity RatioN/A Current Ratio3.63 Quick Ratio3.63 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$71.64 million Price / Sales3.51 Cash FlowN/A Price / CashN/A Book Value$5.18 per share Price / Book1.49 Profitability EPS (Most Recent Fiscal Year)($0.57) Net Income$-16,440,000.00 Net Margins-47.73% Return on Equity-19.90% Return on Assets-10.22% Miscellaneous Employees112 Outstanding Shares32,480,000Market Cap$254.35 Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.09. The business had revenue of $11.20 million for the quarter, compared to analysts' expectations of $13.33 million. Jounce Therapeutics had a negative net margin of 47.73% and a negative return on equity of 19.90%. View Jounce Therapeutics' Earnings History. When is Jounce Therapeutics' next earnings date? Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Jounce Therapeutics. What price target have analysts set for JNCE? 6 brokers have issued 1 year price objectives for Jounce Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate Jounce Therapeutics' share price to reach $14.80 in the next year. This suggests a possible upside of 91.2% from the stock's current price. View Analyst Ratings for Jounce Therapeutics. What is the consensus analysts' recommendation for Jounce Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Jounce Therapeutics' key competitors? Some companies that are related to Jounce Therapeutics include BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL), Heska (HSKA), La Jolla Pharmaceutical (LJPC), Avrobio (AVRO), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Voyager Therapeutics (VYGR), Translate Bio (TBIO), Mesoblast (MESO), Nightstar Therapeutics (NITE), Novavax (NVAX) and Surface Oncology (SURF). Who are Jounce Therapeutics' key executives? Jounce Therapeutics' management team includes the folowing people: Dr. Richard Murray, Pres, CEO & Director (Age 59)Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 53)Dr. Elizabeth G. Trehu, Chief Medical Officer (Age 58)Dr. James P. Allison, FounderDr. Thomas F. Gajewski, Founder When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. Has Jounce Therapeutics been receiving favorable news coverage? News articles about JNCE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Jounce Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also assigned media coverage about the company an impact score of 46.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of Jounce Therapeutics? Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $7.74. How big of a company is Jounce Therapeutics? Jounce Therapeutics has a market capitalization of $254.35 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840. MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 139 (Vote Outperform)Underperform Votes: 110 (Vote Underperform)Total Votes: 249MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?